Related Experiment Videos
Betaxolol in chronic obstructive pulmonary disease
Journal of Ocular Pharmacology
|January 1, 1987
Summary
Betaxolol, a beta-blocker, showed no significant negative impact on pulmonary function tests in glaucoma patients with COPD. This study supports betaxolol as a safer option for patients needing beta-blocker therapy.
Area of Science:
- Pulmonary Medicine
- Ophthalmology
- Pharmacology
Background:
- Beta-blockers are commonly prescribed for glaucoma and cardiovascular conditions.
- Some beta-blockers can exacerbate chronic obstructive pulmonary disease (COPD).
- Betaxolol is a cardioselective beta-blocker with a potential for fewer pulmonary side effects.
Purpose of the Study:
- To evaluate the effect of betaxolol on pulmonary function tests in patients with both glaucoma and COPD.
- To determine if betaxolol therapy significantly alters lung function in this patient population.
Main Methods:
- Prospective study involving nine patients with glaucoma and COPD requiring beta-blocker therapy.
- Pulmonary function tests (FEV-1, FVC, FEV-1/FVC ratio) were conducted before and after two weeks of betaxolol treatment.
Main Results:
- No statistically significant changes were observed in the mean FEV-1/FVC ratio, mean FEV-1, or mean FVC after two weeks of betaxolol therapy (P > 0.05).
- The mean FEV-1/FVC ratio changed from 59.33% to 57.89%.
- Mean FEV-1 and FVC values showed minimal, non-significant alterations.
Conclusions:
- Betaxolol appears to be safe regarding pulmonary function in patients with glaucoma and COPD.
- These findings support previous evidence suggesting betaxolol as a potentially advantageous beta-blocker for patients at risk of pulmonary side effects.
- This study represents the largest single-center series investigating betaxolol's pulmonary effects in this specific patient group.